← Leaderboards
Steven W. Dow
National Jewish Health
$7,055,635
Attributed
$8,444,390
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,444,390 · 7
By mechanism
U01$4,348,005 · 2
U54$2,208,182 · 2
R01$1,274,044 · 1
R21$614,159 · 2
Top collaborators
- Cheryl A London4 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsLungBaseAnimal ModelMelanomaT-LymphocyteResistanceLaboratory MouseVirulentBurkholderia PseudomalleiChronicPathogenInfectionBreathingAdjuvantBurkholderiaAcuteComplexImmuneResponseImmune ResponseLiposomesAntineoplasticsGene Therapy
Grant awards (26)
Novel Immunotherapy Targeting Local and Systemic Immunity for Treatment of Ocular Surface Squamous Neoplasia$215,985
R21 · FY2025 · CA · contact PI
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma$552,171
U01 · FY2022 · CA · contact PI
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma$1
U01 · FY2021 · CA · contact PI
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma$553,260
U01 · FY2020 · CA · contact PI
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma$1,672,078
U01 · FY2017 · CA · contact PI
Mucosal immunization for cross-protection against pneumonic burkholderia$229,343
U54 · FY2013 · AI · contact PI
Mucosal immunization for cross-protection against pneumonic burkholderia$310,630
U54 · FY2012 · AI · contact PI
Mechanisms of Enteric Burkholderia psuedomallei infection$217,462
R21 · FY2012 · AI · contact PI
Mucosal immunization for cross-protection against pneumonic burkholderia$222,278
U54 · FY2011 · AI · contact PI
Mechanisms of Enteric Burkholderia psuedomallei infection$180,712
R21 · FY2011 · AI · contact PI
Mucosal immunization for cross-protection against pneumonic burkholderia$248,448
U54 · FY2010 · AI · contact PI
Mucosal immunization for cross-protection against pneumonic burkholderia$214,888
U54 · FY2009 · AI · contact PI
Innate Immunity to Pneumonic Burkholderia Infection$255,340
U54 · FY2008 · AI · contact PI
Innate Immunity to Pneumonic Burkholderia Infection$293,054
U54 · FY2007 · AI · contact PI
Antigen Presentation and Pulmonary Immunity to Plague$442,065
U01 · FY2006 · AI · contact PI
Innate Immunity to Pneumonic Burkholderia Infection$217,754
U54 · FY2006 · AI · contact PI
Antigen Presentation and Pulmonary Immunity to Plague$441,176
U01 · FY2005 · AI
Innate Immunity to Pneumonic Burkholderia Infection$216,447
U54 · FY2005 · AI
Antigen Presentation and Pulmonary Immunity to Plague$428,327
U01 · FY2004 · AI
TUMOR ANGIOGENESIS INHIBITIION BY SYSTEMIC GENE DELIVERY$326,250
R01 · FY2004 · CA
TUMOR ANGIOGENESIS INHIBITIION BY SYSTEMIC GENE DELIVERY$326,250
R01 · FY2003 · CA
Antigen Presentation and Pulmonary Immunity to Plague$258,927
U01 · FY2003 · AI
TUMOR ANGIOGENESIS INHIBITIION BY SYSTEMIC GENE DELIVERY$283,725
R01 · FY2002 · CA
TUMOR ANGIOGENESIS INHIBITIION BY SYSTEMIC GENE DELIVERY$163,125
R01 · FY2001 · CA
TUMOR ANGIOGENESIS INHIBITIION BY SYSTEMIC GENE DELIVERY$9,900
R01 · FY2001 · CA
TUMOR ANGIOGENESIS INHIBITIION BY SYSTEMIC GENE DELIVERY$164,794
R01 · FY2000 · CA